The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma

Bibliography

• Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-9
   PubMed Web of Science ®Google Scholar
• Tsuchiya J, Murakami H, Kanoh T, et al. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol 1994;87:832-4
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000;82:1254-60
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-14
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8. quiz 982
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-96
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-55
   PubMed Web of Science ®Google Scholar
• van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood 2014;124:328-33
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-25
   PubMed Web of Science ®Google Scholar
• Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119:5661-70
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02. Blood 2013;121:1968-75
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970-5
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts. Atlanta, GA; 2012. 120:74
   Google Scholar
• Bringhen S, Cavallo F, Petrucci M, et al. Carfilzomib, cyclophosphamide and dexamethasone (CCD) for newly diagnosed multiple myeloma (MM) patients: initial results of a multicenter, open label phase II study. Haematologica 2013;98:Abstract 5578
   Google Scholar
• Mikhael JR, Reeder CB, Libby ENIII, et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts. Atlanta, GA; 2012. 120:445
   Google Scholar
• Touzeau C, Kolb B, Hulin C, et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): results of a phase (Ph) I/II trial. ASCO Meeting Abstracts 2013. 31:8513
   Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525-42
   PubMed Web of Science ®Google Scholar
• Romano A, Conticello C, Cavalli M. Salvage therapy of multiple myeloma: the new generation drugs. 2014;2014:456037
   Google Scholar
• Chen Q, Lin J, Jinno S, Okayama H. Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation. Oncogene 2003;22:992-1001
   PubMed Web of Science ®Google Scholar
• Harbour JW, Luo RX, Dei Santi A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859-69
   PubMed Web of Science ®Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61
   PubMed Web of Science ®Google Scholar
• Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994;14:2077-86
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Sellers WR, Kaelin WGJr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15:3301-12
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38
   PubMed Web of Science ®Google Scholar
• Rocca A, Farolfi A, Bravaccini S, et al. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 2014;15:407-20
   PubMed Web of Science ®Google Scholar
• Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle 2013;12:1892-900
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119:4597-607
   PubMed Web of Science ®Google Scholar
• Li C, Qi L, Bellail AC, et al. PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis. Oncol Lett 2014;7:1673-8
   PubMed Web of Science ®Google Scholar
• Barton KL, Misuraca K, Cordero F, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One 2013;8:e77639
   PubMed Web of Science ®Google Scholar
• Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res 2013;33:2997-3004
   PubMed Web of Science ®Google Scholar
• Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-8
   PubMed Web of Science ®Google Scholar
• Liu F, Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther 2012;11:2138-48
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66:7661-7
   PubMed Web of Science ®Google Scholar
• Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008;68:5519-23
   PubMed Web of Science ®Google Scholar
• Katsumi Y, Iehara T, Miyachi M, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun 2011;413:62-8
   PubMed Web of Science ®Google Scholar
• Whiteway SL, Harris PS, Venkataraman S, et al. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol 2013;111:113-21
   PubMed Web of Science ®Google Scholar
• Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406
   PubMed Web of Science ®Google Scholar
• Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene 2014;33:1890-903
   PubMed Web of Science ®Google Scholar
• Sherr CJ. D-type cyclins. Trends Biochem Sci 1995;20:187-90
   PubMed Web of Science ®Google Scholar
• Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393-409
   PubMed Web of Science ®Google Scholar
• Mundle SD, Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J 2003;17:569-74
   PubMed Web of Science ®Google Scholar
• Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703
   PubMed Web of Science ®Google Scholar
• Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002;3:11-20
   PubMed Web of Science ®Google Scholar
• Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Fiore F, Eytan E, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181-9
   PubMed Web of Science ®Google Scholar
• Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92:12146-50
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12
   PubMed Web of Science ®Google Scholar
• Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011;20:620-34
   PubMed Web of Science ®Google Scholar
• Gemenetzidis E, Elena-Costea D, Parkinson EK, et al. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 2010;70:9515-26
   PubMed Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013;19:6173-82
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J, Bartkova J. Perspective: defects in cell cycle control and cancer. J Pathol 1999;187:95-9
   PubMed Web of Science ®Google Scholar
• Bartkova J, Lukas J, Bartek J. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog Cell Cycle Res 1997;3:211-20
   PubMedGoogle Scholar
• Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108
   PubMed Web of Science ®Google Scholar
• Kaelin WGJr. Alterations in G1/S cell-cycle control contributing to carcinogenesis. Ann N Y Acad Sci 1997;833:29-33
   PubMed Web of Science ®Google Scholar
• Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52
   PubMed Web of Science ®Google Scholar
• Hirai H, Roussel MF, Kato JY, et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81
   PubMed Web of Science ®Google Scholar
• Kulkarni MS, Daggett JL, Bender TP, et al. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002;16:127-34
   PubMed Web of Science ®Google Scholar
• Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002;21:1510-17
   PubMed Web of Science ®Google Scholar
• Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20(13):3379-83
   PubMed Web of Science ®Google Scholar
• Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345-53
   PubMed Web of Science ®Google Scholar
• Shaughnessy JJr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98:217-23
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99:3735-41
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579-83
   PubMed Web of Science ®Google Scholar
• Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003;102:1588-94
   PubMed Web of Science ®Google Scholar
• Zandecki M, Facon T, Preudhomme C, et al. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma 1995;18:497-503
   PubMed Web of Science ®Google Scholar
• Juge-Morineau N, Mellerin MP, Francois S, et al. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995;91:664-7
   PubMed Web of Science ®Google Scholar
• Dick FA. Structure-function analysis of the retinoblastoma tumor suppressor protein - is the whole a sum of its parts? Cell Div 2007;2:26
   PubMed Web of Science ®Google Scholar
• McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8
   PubMed Web of Science ®Google Scholar
• Breault GA, Ellston RP, Green S, et al. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorg Med Chem Lett 2003;13:2961-6
   PubMed Web of Science ®Google Scholar
• Mesguiche V, Parsons RJ, Arris CE, et al. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett 2003;13:217-22
   PubMed Web of Science ®Google Scholar
• Kim KS, Kimball SD, Misra RN, et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002;45:3905-27
   PubMed Web of Science ®Google Scholar
• Misra RN, Rawlins DB, Xiao HY, et al. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett 2003;13:1133-6
   PubMed Web of Science ®Google Scholar
• Nugiel DA, Vidwans A, Etzkorn AM, et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. J Med Chem 2002;45:5224-32
   PubMed Web of Science ®Google Scholar
• Toogood PL. Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 2001;21:487-98
   PubMed Web of Science ®Google Scholar
• Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22:723-38
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009;16:36-43
   PubMed Web of Science ®Google Scholar
• Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45
   PubMed Web of Science ®Google Scholar
• Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32
   PubMed Web of Science ®Google Scholar
• Huang X, Jayabalan D, Liberto MD, et al. Synergistic Loss of IRF4 and Induction of IRF7 sensitizes primary myeloma cells to IMiD killing by IFN{beta} in prolonged early G1 arrest induced by CDK4/CDK6 inhibition. ASH Annual Meeting Abstracts; Atlanta, GA. 2012. 120:572
   Google Scholar
• Huang X, Liberto MD, Jayabalan D, et al. Lenalidomide targets myeloma cells preferentially during prolonged early G1 arrest but not synchronization into s phase by selective and reversible inhibition of CDK4/CDK6 through loss of IRF-4. ASH Annual Meeting Abstracts; Orlando, FL. 2010. 116:449
   Google Scholar
• Feng R, Huang X, Coulton L, et al. Targeting CDK4/CDK6 impairs osteoclast progenitor pool expansion and blocks osteolytic lesion development in multiple myeloma. ASH Annual Meeting Abstracts; New Orleans, LA. 2009. 114:298
   Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-8
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76
   PubMed Web of Science ®Google Scholar
• Flinn R, Crown J, Lang I, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) [abstract CT101]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014; 5-9 Apr 2014; San Diego, CA; AACR
   Google Scholar
• DiLiberto M, Mason CE, Ely SA, et al. The combination Of Palbociclib plus bortezomib is safe and active in patients with previously treated mantle cell lymphoma: final results of a phase I trial. Blood 2013;122:4393-3
   Google Scholar
• Niesvizky R, Lentzsch S, Badros AZ, et al. A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2010. 116:860
   Google Scholar
• Niesvizky R, Costa LJ, Haideri NA, et al. Preliminary Results of a Phase 2 Study of PD 0332991 in combination with bortezomib and dexamethasone in patients with relapsed and refractory multiple myeloma. ASH Annual Meeting Abstracts; San Diego, CA. 2011. 118:2940
   Google Scholar
• Holkova B, Badros AZ, Geller R, et al. A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma. ASH Annual Meeting Abstracts; San Diego, CA. 2011. 118:2931
   Google Scholar
• Siegel DS, Krishnan A, Lonial S, et al. Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). ASH Annual Meeting Abstracts; Orlando, FL. 2006. 108:3580
   Google Scholar
• Mateos MV, Cibeira MT, Richardson PG, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 2010;16:3260-9
   PubMed Web of Science ®Google Scholar
• Lehners N, Andrulis M, Capper D, et al. BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. ; ASH Annual Meeting Abstracts; Atlanta, GA. 2012. 120:4040
   Google Scholar